CEBPA and acute myeloid leukemia: In particular, in vitro studies demonstrated that calreticulin expression was upregulated via activation of the ATF6 pathway in AML cells, thereby ultimately suppressing translation of C/EBPα and contributing to the block in myeloid differentiation and cell-cycle deregulation which represent distinctive features of this leukemic phenotype.